Clinical trial
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients…
NCT00132769 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00132769 |
|---|---|
| Title | A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED) |
| Official title | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | MK-0873, Comparator: Placebo |
| Enrollment | 106 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Aug 22, 2005 |
| Last update posted | Jul 30, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: